Characterization of Tumor Response with Lenvatinib Plus Pembrolizumab in Study 309/KEYNOTE-775 (177)

In Study 309/KEYNOTE-775, patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib + pembrolizumab (LEN + pembro) demonstrated statistically significant and clinically meaningful improvements in efficacy versus chemotherapy. In pts. randomly assigned to LEN + pembro, the objective response rate (ORR) was 31.9% in the overall population and 30.3% in the mismatch-repair proficient (pMMR) population. Here we report additional tumor-response analyses in the LEN + pembro arm of Study 309/KEYNOTE-775 at the March 1, 2022, data cutoff (>16 months of additional follow-up from the primary analysis).